Resistance-Guided Antimicrobial Therapy Using Doxycycline–Moxifloxacin and Doxycycline–2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability
- 20 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (6) , 1461-1468
Abstract
Background: Macrolide resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions, and quinolone resistance is increasing. We recently reported that resistance-guided therapy (RGT) using doxycycline followed by sitafloxacin or 2.5 g azithromycin cured 92% and 95% of macrolide-resistant and macrolide-susceptible infections, respectively. We present data on RGT using doxycycline–moxifloxacin, the regimen recommended in international guidelines, and extend data on the efficacy of doxycycline–2.5 g azithromycin and de novo macrolide resistance. Methods: Patients attending Melbourne Sexual Health Centre between 2017 and 2018 with sexually transmitted infection syndromes were treated with doxycycline for 7 days and recalled if MG-positive. Macrolide-susceptible cases received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and resistant cases moxifloxacin (400 mg daily, 7 days). Test of cure was recommended 14–28 days post-antimicrobials. Results: There were 383 patients (81 females/106 heterosexual males/196 men who have sex with men) included. Microbial cure following doxycycline–azithromycin was 95.4% (95% confidence interval [CI], 89.7–98.0) and doxycycline–moxifloxacin was 92.0% (95% CI, 88.1–94.6). De novo macrolide resistance was detected in 4.6% of cases. Combining doxycycline–azithromycin data with our prior RGT study (n = 186) yielded a pooled cure of 95.7% (95% CI, 91.6–97.8). ParC mutations were present in 22% of macrolide-resistant cases. Conclusions: These findings support the inclusion of moxifloxacin in resistance-guided strategies and extend the evidence for 2.5 g azithromycin and presumptive use of doxycycline. These data provide an evidence base for current UK, Australian, and European guidelines for the treatment of MG.Keywords
Funding Information
- National Health and Medical Research Council (1091536, 1091226)
This publication has 36 references indexed in Scilit:
- Transmission and Selection of Macrolide Resistant Mycoplasma genitalium Infections Detected by Rapid High Resolution Melt AnalysisPLOS ONE, 2012
- Mycoplasma genitalium: from Chrysalis to Multicolored ButterflyClinical Microbiology Reviews, 2011
- 'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women.'BMC Infectious Diseases, 2011
- Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistanceInternational Journal of Antimicrobial Agents, 2010
- Azithromycin Treatment Failure inMycoplasma genitalium–Positive Patients with Nongonococcal Urethritis Is Associated with Induced Macrolide ResistanceClinical Infectious Diseases, 2008
- Persistence of Mycoplasma genitalium Following Azithromycin TherapyPLOS ONE, 2008
- Azithromycin Failure inMycoplasma genitaliumUrethritisEmerging Infectious Diseases, 2006
- Etiologies of Nongonococcal Urethritis: Bacteria, Viruses, and the Association with Orogenital ExposureThe Journal of Infectious Diseases, 2006
- In Vitro Development of Resistance to Six and Four Fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis , RespectivelyAntimicrobial Agents and Chemotherapy, 2005
- Association of Mycoplasma genitalium with acute non-gonococcal urethritisThe Lancet, 1993